# US 2023/0068663 A1 · Novel lilrb2 antibodies and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0068663 A1
- Document ID: US20230068663A1
- Status: Published application
- Kind: A1
- Application number: 17/759,800
- Filed: 2021-01-28
- Published: 2023-03-02
- Earliest claimed: 2020-02-05
- Assignees: Board of Regents, The University of Texas System; Immune-Onc Therapeutics, Inc.
- Applicants: The Board of Regents of the University of Texas System; Immune-Onc Therapeutics, Inc.
- Inventors: Zhiqiang AN; Ningyan ZHANG; Zhiqiang KU; Chengcheng ZHANG; Xiaoye XU; Heyu CHEN; JingJing XIE; Maria Jose COSTA; An SONG; X. Charlene LIAO
- Web page: https://patentgrep.com/patent/US20230068663A1

## CPC

- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided herein are antibodies binding to LILRB2 and the uses of the antibodies in detecting and treating cancer and autoimmune diseases.

## Claims

### Claim 1

An isolated monoclonal antibody or an antigen-binding fragment thereof comprising a heavy chain (HC) variable region (VH) and a light chain (LC) variable region (VL) comprising clone-paired CDR sequences as set forth in Table 2; and variants thereof wherein one or more of the HC-CDRs and/or LC-CDRs has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof.

### Claim 2 (depends on 1)

The isolated monoclonal antibody or an antigen binding fragment thereof of claim 1, wherein the isolated monoclonal antibody is a murine, a rodent, a rabbit, a chimeric, humanized, or human antibody.

### Claim 3 (depends on 1)

The isolated monoclonal antibody or an antigen-binding fragment thereof of claim 1, wherein the antigen-binding fragment is a recombinant ScFv (single chain fragment variable) antibody, Fab fragment, F(ab′)2 fragment, or Fv fragment.

### Claim 4 (depends on 1)

The isolated monoclonal antibody or an antigen binding fragment thereof of claim 1, wherein the isolated monoclonal antibody is a human antibody.

### Claim 5 (depends on 1)

The isolated monoclonal antibody or an antigen-binding fragment thereof of claim 1, wherein the VH and VL chains have amino acid sequences at least 90% or 95% identical to clone-paired sequences of Appendices II and IV, respectively.

### Claim 6 (depends on 1)

The isolated monoclonal antibody or an antigen-binding fragment thereof of claim 1, wherein the VH and VL chains are encoded by nucleic acid sequences at least 80% or 90% identical to clone-paired sequences of Appendices I and III respectively.

### Claim 7 (depends on 5)

The isolated monoclonal antibody or an antigen-binding fragment thereof of claim 5, wherein the VH and VL chains have amino acid sequences identical to clone-paired sequences of Appendices II and IV, respectively.

### Claim 8 (depends on 5)

The isolated monoclonal antibody or an antigen binding fragment thereof of claim 5, wherein the VH and VL chains are encoded by nucleic acid sequences identical to clone-paired sequences of Appendices I and III respectively.

### Claim 9 (depends on 1)

The isolated monoclonal antibody or an antigen binding fragment thereof of claim 1, wherein the isolated monoclonal antibody is a humanized antibody.

### Claim 10 (depends on 1)

The isolated monoclonal antibody or an antigen binding fragment thereof of claim 1, wherein the antibody is a chimeric antibody.

### Claim 11 (depends on 1)

The isolated monoclonal antibody or an antigen binding fragment thereof of claim 1, which induces the activation of LILRB2.

### Claim 12 (depends on 1)

The isolated monoclonal antibody or an antigen binding fragment thereof of claim 1, which suppresses the activation of LILRB2.

### Claim 13 (depends on 1)

An isolated monoclonal antibody or an antigen binding fragment thereof, which competes for the same epitope with the isolated monoclonal antibody or an antigen-binding fragment thereof according to claim 1.

### Claim 14 (depends on 1)

A pharmaceutical composition comprising the isolated monoclonal antibody or an antigen-binding fragment thereof according to claim 1, and a pharmaceutically acceptable carrier.

### Claim 15 (depends on 1)

An isolated nucleic acid that encodes the isolated monoclonal antibody according to claim 1.

### Claim 16 (depends on 15)

A vector comprising the isolated nucleic acid of claim 15.

### Claim 17 (depends on 16)

A host cell comprising the vector of claim 16.

### Claim 18 (depends on 17)

The host cell of claim 17, wherein the host cell is a mammalian cell.

### Claim 19 (depends on 17)

The host cell of claim 17, wherein the host cell is a CHO cell.

### Claim 20 (depends on 1)

A hybridoma or engineered cell encoding and/or producing the isolated monoclonal antibody according to claim 1.

### Claim 21 (depends on 17)

A process of producing an antibody, comprising culturing the host cell of claim 17 under conditions suitable for expressing the antibody, and recovering the antibody.

### Claim 22 (depends on 1)

A chimeric antigen receptor (CAR) protein comprising an antigen-binding fragment according to claim 1.

### Claim 23 (depends on 22)

An isolated nucleic acid that encodes a CAR protein of claim 22.

### Claim 24 (depends on 23)

A vector comprising the isolated nucleic acid of claim 23.

### Claim 25 (depends on 23)

An engineered cell comprising the isolated nucleic acid of claim 23.

### Claim 26 (depends on 25)

The engineered cell of claim 25, wherein the cell is a T cell, NK cell, or macrophage.

### Claim 27 (depends on 1)

A method of treating or ameliorating the effect of a cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of the antibody or an antigen-binding fragment thereof according to claim 1.

### Claim 28 (depends on 27)

The method of claim 27, wherein the method reduces or eradicates the tumor burden in the subject.

### Claim 29 (depends on 27)

The method of claim 27, wherein the method reduces the number of tumor cells and/or slows tumor growth rate.

### Claim 30 (depends on 27)

The method of claim 27, wherein the method reduces tumor size.

### Claim 31 (depends on 27)

The method of claim 27, wherein the method reduces or prevents tumor metastasis.

### Claim 32 (depends on 27)

The method of claim 27, wherein the method eradicates the tumor in the subject.

### Claim 33 (depends on 27)

The method of claim 27, wherein the cancer is a solid cancer.

### Claim 34 (depends on 33)

The method of claim 33, wherein the solid cancer is selected from the group consisting of adrenal cancer, bile duct carcinoma, bone cancer, brain cancer, breast cancer, cervical cancer, choriocarcinoma, colon cancer, colorectal cancer, esophageal cancer, eye cancer, gastric cancer, glioblastoma, head and neck cancer, kidney cancer, liver cancer, lung cancer, mesothelioma, melanoma, merkel cell cancer, nasopharyngeal carcinoma, neuroblastoma, oral cancer, ovarian cancer, pancreatic cancer, penile cancer, pinealoma, prostate cancer, renal cell cancer, retinoblastoma, sarcoma, skin cancer, testicular cancer, thymic carcinoma, thyroid cancer, uterine cancer, and vaginal cancer.

### Claim 35 (depends on 27)

The method of claim 27, wherein the monocytes, macrophages, dendritic cells, neutrophils and other myeloid cells, myeloid-derived suppressor cells, and tumor-associated macrophages are targeted.

### Claim 36 (depends on 27)

The method of claim 27, wherein the cancer is a hematologic malignancy.

### Claim 37 (depends on 36)

The method of claim 36, wherein the hematologic malignancy is selected from the group consisting of acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), B-cell leukemia, chronic lymphoblastic leukemia (CLL), blastic plasmacytoid dendritic cell neoplasm (BPDCN), chronic myelomonocytic leukemia (CMML), chronic myelocytic leukemia (CML), pre-B acute lymphocytic leukemia (Pre-B ALL), diffuse large B-cell lymphoma (DLBCL), extranodal NK/T-cell lymphoma, hairy cell leukemia, heavy chain disease, HHV8-associated primary effusion lymphoma, plasmablastic lymphoma, primary CNS lymphoma, primary mediastinal large B-cell lymphoma, T-cell/histiocyte-rich B-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, Waldenstrom's macroglobulinemia, multiple myeloma (MM), myelodysplastic syndromes (MDS), myeloproliferative neoplasms, and polycythemia vera.

### Claim 38 (depends on 27)

The method of claim 27, wherein the antibody or an antigen-binding fragment thereof is administered intravenously, intra-arterially, intra-tumorally, or subcutaneously.

### Claim 39 (depends on 27)

The method of claim 27, further comprising administering to the subject one or more drugs selected from the group consisting of a topoisomerase inhibitor, an anthracycline topoisomerase inhibitor, an anthracycline, a daunorubicin, a nucleoside metabolic inhibitor, a cytarabine, a hypomethylating agent, a low dose cytarabine (LDAC), a combination of daunorubicin and cytarabine, a daunorubicin and cytarabine liposome for injection, Vyxeos®, an azacytidine, Vidaza®, a decitabine, an all-trans-retinoic acid (ATRA), an arsenic, an arsenic trioxide, a histamine dihydrochloride, Ceplene®, an interleukin-2, an aldesleukin, Proleukin®, a gemtuzumab ozogamicin, Mylotarg®, an FLT-3 inhibitor, a midostaurin, Rydapt®, a clofarabine, a farnesyl transferase inhibitor, a decitabine, an IDH1 inhibitor, an ivosidenib, Tibsovo®, an IDH2 inhibitor, an enasidenib, Idhifa®, a smoothened (SMO) inhibitor, a glasdegib, an arginase inhibitor, an IDO inhibitor, an epacadostat, a BCL-2 inhibitor, a venetoclax, Venclexta®, a platinum complex derivative, oxaliplatin, a kinase inhibitor, a tyrosine kinase inhibitor, a PI3 kinase inhibitor, a BTK inhibitor, an ibrutinib, IMBRUVICA®, an acalabrutinib, CALQUENCE®, a zanubrutinib, a PD-1 antibody, a PD-L1 antibody, a CTLA-4 antibody, a LAG3 antibody, an ICOS antibody, a TIGIT antibody, a TIM3 antibody, a CD40 antibody, a 4-1BB antibody, a CD47 antibody, a SIRP1□ antibody or fusions protein, a CD70 antibody, and CLL1 antibody, a CD123 antibody, an antagonist of E-selectin, an antibody binding to a tumor antigen, an antibody binding to a T-cell surface marker, an antibody binding to a myeloid cell or NK cell surface marker, an alkylating agent, a nitrosourea agent, an antimetabolite, an antitumor antibiotic, an alkaloid derived from a plant, a hormone therapy medicine, a hormone antagonist, an aromatase inhibitor, and a P-glycoprotein inhibitor.

### Claim 40 (depends on 27)

The method according to claim 27, wherein said isolated monoclonal antibody or an antigen binding fragment thereof further comprises an antitumor drug linked thereto.

### Claim 41 (depends on 40)

The method of claim 40, wherein said antitumor drug is linked to said antibody through a photolabile linker.

### Claim 42 (depends on 40)

The method of claim 40, wherein said antitumor drug is linked to said antibody through an enzymatically-cleaved linker.

### Claim 43 (depends on 40)

The method of claim 40, wherein said antitumor drug is a toxin, a radioisotope, a cytokine, or an enzyme.

### Claim 44 (depends on 1)

A method of detecting a cancer cell or cancer stem cell in a sample or subject comprising:
(a) contacting a subject or a sample from the subject with the antibody or an antigen-binding fragment thereof according to claim 1; and
(b) detecting binding of said antibody to a cancer cell or cancer stem cell in said subject or sample.

### Claim 45 (depends on 44)

The method of claim 44, wherein the sample is a body fluid or biopsy.

### Claim 46 (depends on 44)

The method of claim 44, wherein the sample is blood, bone marrow, sputum, tears, saliva, mucous, serum, urine or feces.

### Claim 47 (depends on 44)

The method of claim 44, wherein detection comprises immunohistochemistry, flow cytometry, an immunoassay (including ELISA, RIA etc.) or Western blot.

### Claim 48 (depends on 44)

The method of claim 44, further comprising performing steps (a) and (b) a second time and determining a change in detection levels as compared to the first time.

### Claim 49 (depends on 44)

The method of claim 44, wherein said isolated monoclonal antibody or an antigen binding fragment thereof further comprises a label.

### Claim 50 (depends on 49)

The method of claim 49, wherein said label is a peptide tag, an enzyme, a magnetic particle, a chromophore, a fluorescent molecule, a chemo-luminescent molecule, or a dye.

### Claim 51 (depends on 27)

The method according to claim 27, wherein said isolated monoclonal antibody or an antigen binding fragment thereof is conjugated to a liposome or nanoparticle.

### Claim 52 (depends on 1)

A method of treating or ameliorating the effect of an autoimmune disease in a subject, the method comprising administering to the subject a therapeutically effective amount of the antibody or an antigen-binding fragment thereof according to claim 1.

### Claim 53 (depends on 52)

The method of claim 52, wherein the monocytes, macrophages, dendritic cells, and neutrophils and other myeloid cells are targeted.

### Claim 54 (depends on 52)

The method of claim 52, wherein the antibody or an antigen-binding fragment thereof is administered intravenously, intra-arterially, intra-tumorally, or subcutaneously.

### Claim 55 (depends on 52)

The method of claim 52, further comprising administering to the subject one or more drugs selected from the group consisting of a steroid or an NSAID.

### Claim 56 (depends on 52)

The method of claim 52, wherein the autoimmune disease is Guillain-Barre syndrome, Chronic inflammatory demyelinating polyneuropathy, ankylosing spondylitis, psoriatic arthritis, enteropathic arthritis, reactive arthritis, undifferentiated spondyloarthropathy, juvenile spondyloarthropathy, Behcet's disease, enthesitis, ulcerative colitis, Crohn's disease, irritable bowel syndrome, inflammatory bowel disease, fibromyalgia, chronic fatigue syndrome, pain conditions associated with systemic inflammatory disease, systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, juvenile rheumatoid arthritis, juvenile onset diabetes mellitus (also known as Type I diabetes mellitus), Wegener's granulomatosis, polymyositis, dermatomyositis, inclusion body myositis, multiple endocrine failure, Schmidt's syndrome, autoimmune uveitis, Addison's disease, Grave's Disease, Hashimoto's thyroiditis, autoimmune thyroid disease, pernicious anemia, gastric atrophy, chronic hepatitis, lupoid hepatitis, atherosclerosis, multiple sclerosis, amyotrophic lateral sclerosis, hypoparathyroidism, Dressler's syndrome, myasthenia gravis, Eaton-Lambert syndrome, autoimmune thrombocytopenia, idiopathic thrombocytopenic purpura, hemolytic anemia, pemphigus vulgaris, pemphigus, dermatitis herpetiformis, alopecia, scleroderma, progressive systemic sclerosis, CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangtasia), adult onset diabetes mellitus (also known as Type II diabetes mellitus), mixed connective tissue disease, polyarteritis nodosa, systemic necrotizing vasculitis, glomerulonephritis, atopic dermatitis, atopic rhinitis, Goodpasture's syndrome, Chagas' disease, sarcoidosis, rheumatic fever, asthma, anti-phospholipidsyndrome, erythema multiforme, Cushing's syndrome, autoimmune chronic active hepatitis, allergic disease, allergic encephalomyelitis, transfusion reaction, leprosy, malaria, leshmaniasis, trypanosomiasis, Takayasu's arteritis, polymyalgia rheumatica, temporal arteritis, shistosomiasis, giant cell arteritis, eczema, lymphomatoid granulomatosis, Kawasaki's disease, endophthalmitis, psoriasis, erythroblastosis fetalis, eosinophilic faciitis, Shulman's syndrome, Felty's syndrome, Fuch's cyclitis, IgA nephropathy, Henoch-Schonlein purpura, graft versus host disease, transplantation rejection, tularemia, periodic fever syndromes, pyogenic arthritis, Familial Mediterranean Fever, TNF-receptor associated periodic syndrome (TRAPS), Muckle-Wells syndrome, or hyper-IgD syndrome.

### Claim 57 (depends on 1)

A method for enhancing T cell activation in a subject, the method comprising administering to the subject the antibody or an antigen-binding fragment thereof according to claim 1.

### Claim 58 (depends on 1)

A method for modulating M2a macrophage phenotype in a subject, the method comprising administering to the subject the antibody or an antigen-binding fragment thereof according to claim 1.

### Claim 59

A monoclonal antibody that binds to LILRB2 and:
(a) does not bind to LILRA or another LILRB; or
(b) binds to LILRB2 Domain 1 or 4; or
(c) activates or antagonizes LILRB2; or
(d) enhances monocyte inflammatory potential; or
(e) enhances T cell activation; or
(f) modulates M2a macrophage phenotype; or
(g) prevents myeloid-derived suppressor cell function; or
(h) inhibits leukemia cell migration and/or infiltration in vivo.
